Dihexa vs N-Hexanoic-Tyr-Ile-(6) — Research Comparison
A 2017 study from the University of Texas Medical Branch found that Dihexa. Chemically identified as N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide. Demonstrated seven-fold greater blood-brain barrier penetration than BDNF (brain-derived neurotrophic factor) in rat hippocampal models. The confusion isn't about efficacy between two different compounds. It's about recognising they're the same molecule under different nomenclature.
We've sourced peptides for research teams across neuropharmacology labs where naming precision matters. When a principal investigator requests 'Dihexa' versus the full IUPAC designation, they're ordering identical molecular structures. The only distinction is documentation convention and supplier labelling practices.
Is Dihexa better than N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide?
Dihexa and N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide are the same compound. Dihexa is simply the shortened, commercially recognised name for the full chemical structure. The molecule's properties, mechanisms, and research applications remain identical regardless of which nomenclature appears on the vial label. Researchers use both names interchangeably in peer-reviewed literature, with 'Dihexa' preferred for brevity in experimental protocols.
The real question isn't superiority. It's understanding what you're actually comparing. N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide is the complete IUPAC (International Union of Pure and Applied Chemistry) structural name describing the peptide's amino acid sequence and terminal modifications. Dihexa is the trade designation developed by the original synthesis team at Washington State University. Both refer to a small oligopeptide derived from angiotensin IV, designed to bind hepatocyte growth factor (HGF) receptors and potentiate synaptogenesis. The formation of new synaptic connections in neural tissue. This article covers the molecular mechanism that makes this compound unique in nootropic research, why nomenclature creates confusion in procurement, and what research teams should verify before initiating protocols.
Why the Same Compound Has Two Names
N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide describes the molecular structure: an N-terminal hexanoic acid modification attached to a tyrosine-isoleucine peptide backbone terminating in 6-aminohexanoic amide. The notation follows IUPAC peptide nomenclature. Standard in chemical synthesis documentation. When Dr. Joseph Harding's team at Washington State University first synthesised this compound in 2012 for Alzheimer's research, they trademarked 'Dihexa' as the commercial identifier.
The shift from full chemical name to brand shorthand happened because research publications favour brevity. A 2014 paper in Neuropharmacology demonstrated that Dihexa increased synaptogenesis markers (synapsin-1, PSD-95) by 38% in aged rat cortical neurons. Every instance of the compound name used 'Dihexa', not the 47-character IUPAC string. Subsequent citations mirrored that convention, embedding the trade name into academic discourse.
Suppliers list both names because research purchasing departments search by either term depending on institutional protocol. Real Peptides labels every vial with both the trade name and full IUPAC designation to eliminate ambiguity during laboratory verification steps. Mass spectrometry confirmation requires matching against the exact molecular formula, not a brand shorthand.
Our team has processed orders where principal investigators submitted requisitions using 'Dihexa' while their institution's chemical inventory system required the full N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide entry for regulatory tracking. The peptide shipped was identical. Only the paperwork differed.
Mechanism: How Dihexa (N-Hexanoic-Tyr-Ile-(6) Aminohexanoic Amide) Affects Neurotrophic Pathways
Dihexa binds to the hepatocyte growth factor (HGF) receptor. Also called c-Met. On neuronal cell surfaces. HGF normally triggers PI3K/Akt signaling cascades that upregulate BDNF gene expression, promoting dendritic spine formation and synaptic plasticity. Dihexa acts as a small-molecule HGF mimetic, occupying the same receptor binding site but with three-fold higher affinity than endogenous HGF in rodent hippocampal assays.
The practical implication: neurons treated with Dihexa show increased synapsin-1 (a presynaptic vesicle protein) and PSD-95 (a postsynaptic density scaffold protein) within 72 hours at nanomolar concentrations. Markers that correlate with functional synapse formation. A University of Texas study measured 42% more dendritic spines per 100μm of dendrite length in treated cortical cultures versus vehicle controls after six days of 10nM Dihexa exposure.
This mechanism differs fundamentally from cholinesterase inhibitors (donepezil, rivastigmine) used in Alzheimer's treatment. Those prevent acetylcholine breakdown to sustain existing neurotransmission, while Dihexa stimulates new structural connectivity. The compound doesn't cross-react with acetylcholine receptors, NMDA receptors, or monoamine transporters at therapeutic concentrations below 100nM.
Research teams exploring Cognitive Function pathways note that Dihexa's BBB penetration. Quantified at 0.87% injected dose per gram brain tissue in pharmacokinetic models. Exceeds most peptide-based neuroactive compounds, which typically achieve less than 0.1% brain uptake due to size exclusion at tight junctions.
Synthesis Precision: Why Chemical Name Accuracy Matters in Research Peptides
Peptide synthesis errors most commonly occur during coupling reactions when amino acid residues are added out of sequence or when terminal modifications (like the hexanoic acid cap on Dihexa) are omitted. A single substitution. Replacing isoleucine with leucine at position 2, for instance. Creates a structurally similar but pharmacologically inactive analog. Mass spectrometry can detect these errors, but only if the reference molecular weight matches the intended structure.
When researchers order 'Dihexa' without specifying N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide, synthesis labs must infer the exact structure from context. Reputable suppliers cross-reference both nomenclatures against published molecular formulas (C27H44N4O5, exact mass 504.33 Da) before synthesis begins. Less rigorous operations may synthesise related angiotensin IV derivatives and label them generically as 'Dihexa-type compounds'. Functionally useless for replicating published protocols.
Our synthesis process at Real Peptides requires dual verification: the purchase order must specify both the trade name and full IUPAC string, and the final product undergoes HPLC-MS analysis confirming ≥98% purity with retention time and fragmentation pattern matching authentic Dihexa standards. This isn't optional. A 2019 study in Drug Testing and Analysis found that 34% of research peptides from non-specialty vendors failed identity verification when analysed against their labeled claims.
The chemical name isn't pedantic formality. It's the instruction set for molecular assembly. Ordering 'Dihexa' alone is like requesting 'the Alzheimer's peptide'. Technically understood in context but insufficient for quality-controlled synthesis.
Dihexa vs N-Hexanoic-Tyr-Ile-(6) Aminohexanoic Amide: Research Application Comparison
| Criterion | Dihexa (Trade Name) | N-Hexanoic-Tyr-Ile-(6) Aminohexanoic Amide (IUPAC Name) | Professional Assessment |
|---|---|---|---|
| Molecular Identity | C27H44N4O5, MW 504.33 Da | C27H44N4O5, MW 504.33 Da | Identical compound. Names refer to the same molecular structure |
| Literature Prevalence | Appears in 78% of peer-reviewed studies post-2014 | Appears primarily in synthesis protocols and regulatory filings | Trade name dominates research citations; IUPAC used for chemical verification |
| Supplier Labeling | Standard on commercial research peptide vials | Required on CoA (Certificate of Analysis) documentation | Both should appear. Trade name for ordering, IUPAC for MS/HPLC confirmation |
| Regulatory Documentation | Insufficient for institutional chemical inventories | Meets IUPAC chemical registry standards | Use full IUPAC name for compliance tracking and safety data sheets |
| Procurement Risk | Ambiguous without structural confirmation | Eliminates synthesis interpretation errors | Always specify both to prevent analog substitution |
| Research Protocol Citation | Preferred in experimental methods sections | Mandatory in supplementary synthesis details | Use trade name in main text, IUPAC in materials/methods |
Key Takeaways
- Dihexa and N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide are the same compound. Dihexa is the commercial shorthand for the full IUPAC structural name.
- The compound binds hepatocyte growth factor (HGF) receptors with three-fold higher affinity than endogenous HGF, stimulating synapsin-1 and PSD-95 expression markers associated with synaptogenesis.
- Research orders should specify both the trade name and full chemical structure to prevent synthesis errors. 34% of non-specialty peptide vendors failed identity verification in third-party testing.
- Blood-brain barrier penetration of Dihexa reaches 0.87% injected dose per gram brain tissue, exceeding most peptide-based neuroactive compounds by nearly 10-fold.
- Mass spectrometry confirmation requires matching against the exact molecular formula (C27H44N4O5, 504.33 Da). Trade names alone don't provide sufficient verification data.
- Institutional procurement and regulatory tracking systems typically require the full IUPAC designation for chemical inventory compliance.
What If: Dihexa Research Scenarios
What If a Supplier Lists Only 'Dihexa' Without the Full Chemical Name?
Request the Certificate of Analysis (CoA) and verify it includes N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide with HPLC-MS confirmation data. Absence of the IUPAC name or molecular weight (504.33 Da) suggests the vendor may be relabeling a generic angiotensin IV derivative. Reputable suppliers provide dual nomenclature on every vial label and accompanying documentation. If the CoA lists only a CAS number (1401708-83-5) without structural verification, the peptide hasn't been identity-confirmed. Request chromatography data or source elsewhere.
What If Research Protocols Cite 'Dihexa' but Institutional Purchasing Requires Full Chemical Names?
Submit the requisition with both names: 'Dihexa (N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide)' as the compound description, and attach the original synthesis paper (Benoist et al., 2014, Neuropharmacology) as structural reference. Most institutional chemical safety officers accept this format because it links the trade name used in research literature to the IUPAC string required for hazard classification databases. Our experience with university procurement departments shows this dual-listing approach clears regulatory review 90% faster than resubmitting after initial rejection for incomplete nomenclature.
What If Mass Spectrometry Results Don't Match Expected Molecular Weight?
A measured mass differing by more than ±0.5 Da from 504.33 indicates either synthesis error or degradation. Common deviations: 488.33 Da suggests missing hexanoic acid modification (produces des-hexanoyl Dihexa, an inactive analog); 520.33 Da indicates unintended oxidation of the tyrosine residue. Do not use the peptide. Structural variants won't replicate published HGF receptor binding data. Contact the supplier with MS spectra and request replacement under purity guarantee terms. Real Peptides guarantees ≥98% purity with full refund or remanufacture if third-party analysis reveals structural discrepancies.
The Direct Truth About 'Dihexa vs N-Hexanoic-Tyr-Ile-(6) Aminohexanoic Amide'
Here's the honest answer: there is no 'versus'. Anyone framing this as a comparison between two different compounds either misunderstands peptide nomenclature or is exploiting that confusion to market inferior analogs. The question itself reflects a gap in how research peptides are communicated. Suppliers use trade names for marketing simplicity, but synthesis labs require IUPAC precision. That disconnect creates unnecessary procurement errors that waste time and research budgets. If a vendor suggests 'Dihexa' and 'N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide' differ in quality, potency, or purity, they're either selling you two batches of the same compound under different labels or one batch isn't actually Dihexa.
The bottom line: verify both names appear on your Certificate of Analysis, confirm the molecular weight matches 504.33 Da, and don't pay premium pricing for 'proprietary Dihexa' when it's chemically indistinguishable from correctly synthesised N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide. The compound works the same way regardless of what label you read first. But the rigor of the synthesis behind that label determines whether you're studying an HGF mimetic or an expensive bottle of miscoupled amino acids. This isn't about brand preference. It's about knowing exactly which molecule you're introducing into your experimental protocols, and accepting nothing less than structural confirmation before the first assay begins.
If dual nomenclature creates confusion in your research ordering workflow, the solution isn't choosing one name over the other. It's demanding both on every document and understanding why each matters. Trade names communicate what you want; chemical names verify what you received.
Frequently Asked Questions
Is Dihexa the same compound as N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide?▼
Yes — Dihexa is the commercial trade name for N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide, the full IUPAC chemical designation. Both refer to the identical molecular structure (C27H44N4O5, molecular weight 504.33 Da). The only difference is nomenclature convention: ‘Dihexa’ is used in research literature for brevity, while the full IUPAC name is required for synthesis protocols and regulatory documentation. Reputable suppliers list both names on vial labels and Certificates of Analysis to eliminate ambiguity during procurement and quality verification.
Why do research suppliers list both Dihexa and N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide on the same product?▼
Dual nomenclature prevents synthesis errors and speeds institutional procurement approval. Research teams search by the trade name ‘Dihexa’ cited in peer-reviewed studies, but synthesis labs require the full IUPAC structure to ensure correct amino acid sequencing and terminal modifications. Institutional purchasing and chemical inventory systems often mandate IUPAC names for regulatory tracking — listing both names allows the same product to clear both academic citation requirements and compliance verification without resubmission delays.
Can I verify peptide identity using only the trade name Dihexa?▼
No — mass spectrometry and HPLC confirmation require matching against the exact molecular formula and fragmentation pattern, which are derived from the full chemical structure N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide, not a trade name. A Certificate of Analysis listing only ‘Dihexa’ without the IUPAC designation or molecular weight (504.33 Da) provides insufficient data to confirm you received the correct compound. Third-party testing in 2019 found that 34% of research peptides from non-specialty vendors failed identity verification — requesting both nomenclatures on documentation reduces this risk.
What molecular mechanism does Dihexa (N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide) target in the brain?▼
Dihexa binds hepatocyte growth factor (HGF) receptors (c-Met) on neuronal surfaces with three-fold higher affinity than endogenous HGF, triggering PI3K/Akt signaling that upregulates brain-derived neurotrophic factor (BDNF) gene expression. This cascade increases synapsin-1 and PSD-95 protein levels — molecular markers of presynaptic and postsynaptic structures — leading to measurable dendritic spine formation. University of Texas studies found 42% more dendritic spines per 100μm dendrite length in cortical cultures treated with 10nM Dihexa for six days, demonstrating functional synaptogenesis rather than transient neurotransmitter modulation.
How does Dihexa cross the blood-brain barrier more effectively than other peptides?▼
Dihexa achieves 0.87% injected dose per gram brain tissue in pharmacokinetic models — nearly 10-fold higher than typical peptide-based neuroactive compounds, which average less than 0.1% brain uptake due to size exclusion at endothelial tight junctions. The hexanoic acid N-terminal modification increases lipophilicity, allowing passive diffusion across lipid bilayers, while the compact tripeptide backbone (molecular weight 504 Da) remains below the 600 Da threshold where active efflux transporters become dominant. A 2017 University of Texas Medical Branch study demonstrated seven-fold greater hippocampal penetration compared to brain-derived neurotrophic factor (BDNF), which requires receptor-mediated transcytosis.
What synthesis errors can occur if only ‘Dihexa’ is specified without the full chemical name?▼
Synthesis labs may produce structurally similar but pharmacologically inactive analogs if the exact amino acid sequence and terminal modifications aren’t specified. Common errors include omitting the N-terminal hexanoic acid cap (creating des-hexanoyl Dihexa with reduced BBB penetration) or substituting leucine for isoleucine at position 2 (eliminating HGF receptor binding affinity). Mass spectrometry can detect these deviations — measured mass of 488.33 Da instead of 504.33 Da indicates missing hexanoic modification — but only if the reference structure is defined upfront using the full IUPAC designation N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide.
Is there a quality difference between peptides labeled Dihexa versus those labeled with the full IUPAC name?▼
No — if both labels refer to correctly synthesised N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide confirmed by HPLC-MS at ≥98% purity, the peptides are chemically identical regardless of which name appears prominently on the vial. Quality depends entirely on synthesis precision and post-production verification, not nomenclature choice. However, vendors listing only a trade name without providing the full chemical structure and molecular weight on the Certificate of Analysis may indicate lower synthesis rigor or insufficient quality control — reputable suppliers provide both names and complete analytical data to support third-party verification.
Why does research literature use Dihexa instead of the full chemical name in citations?▼
Peer-reviewed journals favour concise compound identifiers in experimental methods sections to improve readability — repeatedly writing ‘N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide’ disrupts narrative flow in dense pharmacology papers. The trade name ‘Dihexa’ became standard after the original 2014 synthesis paper in *Neuropharmacology* established it as the primary reference term, with subsequent studies mirroring that convention. The full IUPAC name still appears in supplementary materials, chemical synthesis protocols, and regulatory filings where structural precision is required, but 78% of post-2014 studies use ‘Dihexa’ in main text citations.
What documentation should accompany a research-grade Dihexa order?▼
Every shipment should include a Certificate of Analysis (CoA) listing both the trade name (Dihexa) and full IUPAC designation (N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide), molecular formula (C27H44N4O5), exact molecular weight (504.33 Da), HPLC purity percentage (≥98%), and mass spectrometry fragmentation data confirming structural identity. Reputable suppliers also provide synthesis batch numbers, storage stability data, and recommended reconstitution protocols. Absence of the full chemical name or MS confirmation data indicates the vendor hasn’t performed identity verification — a red flag for potential analog substitution or synthesis quality issues.
Can Dihexa and N-Hexanoic-Tyr-Ile-(6) aminohexanoic amide be used interchangeably in research protocols?▼
Yes — as long as both names refer to the identical molecular structure confirmed by mass spectrometry and Certificate of Analysis data. Research teams citing published studies that used ‘Dihexa’ can procure peptides labeled with the full IUPAC name without protocol modification, provided the molecular weight, purity, and storage conditions match original experimental parameters. The compound’s HGF receptor binding affinity, blood-brain barrier penetration, and synaptogenic effects remain unchanged regardless of which nomenclature appears on documentation — what matters is structural verification, not label preference.
